ea0015p362 | Thyroid | SFEBES2008
Paschalidis E
, Mallick UK
, Morris M
, Perros P
Introduction: Part of the long-term management of patients with differentiated thyroid cancer (DTC) is TSH suppression with supraphysiological doses of levothyroxine. Anecdotal experience suggests that GPs often are not aware of the differences in objectives between treating patients with DTC with suppressive doses of thyroxine and treating patients with primary hypothyroidism, thus leading to inappropriate adjustments of the dose of levothyroxine.Object...